Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: The disclosure relates to a therapeutic composition for treating L. monocytogenes infection or L. monocytogenes colonization, the composition including at least one, at least two, at least three, or all of an isolated C. saccharogumia bacteria, an isolated C. ramosum bacteria, an isolated C. hathewayi bacteria, and/or an isolated B. producta bacteria in a formulation suitable for administration to a subject. The disclosure further provides similar compositions lacking an isolated C. saccharogumia bacteria. The disclosure additionally provides methods of treating L. monocytogenes infection or colonization using such compositions.

Abstract: The present disclosure relates to an enzyme-immobilized porous membrane and a preparation method of antibiotics using the same, and more specifically, to an enzyme-immobilized porous membrane prepared by immobilizing a specific enzyme through dead-end filtration, and a preparation method of antibiotics with a high yield using the enzyme-immobilized porous membrane. According to various exemplary embodiments of the present disclosure, the enzyme capable of promoting the synthesis reaction of the antibiotic substance is able to be stably immobilized in the porous membrane by passing the solution of enzyme through the membrane. In addition, it is possible to provide antibiotics with a high yield by preparing the antibiotics by passing the reactant solution through the enzyme-immobilized porous membrane.

Abstract: The current invention provides for a microbial consortium comprising one or more ammonium-oxidizing strains which are generally recognized as safe (GRAS) and which are selected from the group of Nitrosomonas, Nitrosospira, Nitrosopumilus, Cenarchaeum, Nitrosoarchaeum, Nitrosocaldus, Caldiarchaeum; and one or more GRAS strains which are commensal to the one or more ammonium-oxidizing strains, and which are selected from the group of Acinetobacter, Alcaligenes, Arthrobacter, Azospirillum, Azotobacter, Bacillus, Beijerinckia, Enterobacter, Erwinia, Flavobacterium, Rhizobium, Serratia and Deinococcus.

Abstract: A process for producing a fuel from lignocellulosic biomass is disclosed. The process includes obtaining a feedstock comprising lignocellulosic biomass, feeding the feedstock and sulfur dioxide into a pretreatment reactor, wherein a total amount of sulfur dioxide in the pretreatment reactor is greater than 70 wt % based on dry weight lignocellulosic biomass, and heating the feedstock and sulfur dioxide in the pretreatment reactor at one or more temperatures between 110° C. and 150° C. for more than 60 minutes.

Abstract: The invention provides combination therapy for use in treating a bacterial biofilm in a subject comprising (a) a polypeptide having serine protease activity and (b) one or more antibiotic compounds. Also provided are compositions and methods of use of the same.

Abstract: The subject invention provides microbe-based compositions comprising cultivated microorganisms and/or growth by-products thereof, as well as methods and systems for producing and using these compositions. More specifically, the subject invention provides microbe-based compositions comprising biologically pure yeast selected from the Pichia clade, and/or growth by-products thereof, such as biosurfactants, enzymes and solvents. Methods of using these compositions to enhance production in agriculture, horticulture, livestock rearing and aquaculture industries are also provided.

Abstract: The abstract particularly describes the nature of this invention and the manner in which it is to be performed:— 1. Specific process and apparatus developed The inventor has prepared a novel process to speedily and accurately detect pathogens present in a fluid sample, identify the pathogens and it's count and determine the level of their susceptibility levels to multiple antimicrobial agents and portability of the apparatus for speedy determination of antibiotic susceptibility levels of pre-separated pathogens from a biological sample cultured in a multi-well strip, in any field location 2. Disadvantage and shortcomings in earlier method and benefit of this invention It provides result in a ready to use format in four hours time from the start of the assay as against the waiting period of 48 to 72 hours for a sample cultured and tested in a lab using the conventional clinical microbiology.

Abstract: The process of making a mineralized mycelium scaffolding requires obtaining a scaffold of fungal biopolymer having a network of interconnected mycelia cells, functionalizing the biopolymer to create precursor sites and thereafter mineralizing the scaffold with one of silicates, apatites and carbonates. The mineralized mycelium scaffolding may be used for medical applications in place of mineralized collagen membranes and collagen/hydroxyapatite composite scaffolds.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: An anti-inflammatory composition of Candida albicans which comprises heat-killed Candida albicans in combination with a neuroprotective supplement. The composition provides a method of stimulating a host immune response capable of reducing a total Candida albicans yeast load below the threshold necessary for the host to keep the Candida albicans yeast and related yeast species in a commensal, non-invasive state. This effect inhibits or prevents chronic inflammation related to invasive Candida genus and allows the composition to be useful for the prevention, prophylaxis, and/or treatment of chronic inflammatory conditions, as well as diseases and disorders of the central nervous system resulting from high L-glutamate levels due to Candida albicans in the gastrointestinal system.

Abstract: The present invention relates generally to medicine. More specifically the invention relates to the use of synergistic probiotic bacteria as intervention for health. In particular, the present invention provides a strain of Faecalibacterium prausnitzii and a bacterial strain which has one or more of the characteristics of: (i) being acetate producing, (ii) being lactate consuming and (iii) having the ability to be an electron acceptor, for use in the treatment or prevention of a disease associated with reduced butyrate levels or a disease associated with reduced or low numbers of Faecalibacterium prausnitzii bacteria.

Abstract: An object of the present invention is to provide a novel method for controlling enzyme productivity of a microorganism. A pulsed electric field is applied to a microorganism to control the enzyme productivity of the microorganism.

Abstract: Compositions comprising a rhodanese with a phosphate-binding motif and methods of detoxifying bacterial endotoxins with such compositions.

Abstract: A method for treating a skin disorder, e.g., acne, e.g. acne vulgaris, in a subject is provided. The method comprises administering, e.g., applying, e.g., topically administering, ammonia oxidizing bacteria, e.g., a preparation comprising ammonia oxidizing bacteria, to a surface of the subject. Preparations comprising ammonia oxidizing bacteria for treating such skin disorder, e.g., acne, e.g. acne vulgaris in a subject are also provided.

Abstract: The present invention relates to a method for preventing and treating hepatic fibrosis, comprising administering an effective amount of plasminogen to a subject.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: The present invention relates to a method for preventing and/or treating overweight/obesity and their related conditions, comprising administering an effective amount of plasminogen to a subject susceptible to or suffering from obesity and its related conditions, to reduce an abnormal/excessive fat deposition at various sites of the body. The present invention further relates to a medicament for preventing and/or treating obesity, and its use in the preparation of a medicament.

Abstract: A method of treating or preventing a microbial infection in a subject is described. The method includes contacting a microorganism within the subject with a composition comprising one or more species of amoebae of the genus Willaertia. Antibiotic wound dressings and kits for providing amoeba for treatment or prevention of microbial infection in a subject are also described.

Abstract: The present invention discloses a stable probiotic composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex for the utilization of lactose and therapeutic management of lactose intolerance. It also discloses a method for the management of lactose intolerance using composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex.